NEW YORK ( TheStreet) -- Shares of Gilead (Nasdaq: GILD) were gapping up Thursday morning with an open price 16.8% higher than Wednesday's closing price. The stock closed at $46.61 Wednesday and opened today's trading at $54.45. The average volume for Gilead has been 9.9 million shares per day over the past 30 days. Gilead has a market cap of $35.3 billion and is part of the health care sector and drugs industry. Shares are up 13.9% year to date as of the close of trading on Wednesday. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. The company has a P/E ratio of 13.1, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full Gilead Ratings Report. Get more investment ideas from our investment research center.